USPTO Examiner SKELDING ZACHARY S - Art Unit 1644

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18906874NOVEL GENE ARMORINGOctober 2024October 2025Allow1221NoNo
18638307COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERSApril 2024June 2024Allow200YesNo
18492221T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONSOctober 2023September 2024Allow1120YesNo
18492310T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONSOctober 2023December 2024Abandon1320YesNo
18228770Chimeric Antigen Receptor Therapies for Treating Solid TumorsAugust 2023July 2025Allow2431YesNo
18358833METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONSJuly 2023January 2024Allow610YesNo
18339197IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOFJune 2023March 2025Allow2121NoNo
18174928METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOODFebruary 2023February 2026Allow3600YesNo
18170941BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFFebruary 2023October 2023Allow810YesNo
18170969BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFFebruary 2023November 2023Allow911YesNo
18169464Antigen Binding Molecules Targeting SARS-CoV-2February 2023December 2023Allow1011NoNo
18069749COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINSDecember 2022December 2023Allow1211YesNo
18066791IMMUNOGLOBULINS BINDING HUMAN VGAMMA9VDELTA2 T CELL RECEPTORSDecember 2022February 2026Allow3810YesNo
18058162SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASESNovember 2022June 2023Allow701NoNo
18055950CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPYNovember 2022January 2026Allow3800NoNo
18055932COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENSNovember 2022February 2026Allow3910NoNo
18048621METHODS FOR INCREASING T-CELL FUNCTIONOctober 2022September 2023Allow1001YesNo
18046408T CELL RECEPTORSOctober 2022December 2025Allow3800YesNo
18045946LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASESOctober 2022March 2026Allow4111YesNo
17948406METHODS FOR CONTROL OF AN INFECTIVE DISEASE WITH A VACCINESeptember 2022December 2025Allow3910NoNo
17910418Use of LactoferrinSeptember 2022January 2026Abandon4010NoNo
17930662HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLSSeptember 2022September 2025Allow3610NoNo
17930018ANTI-CD3 ANTIBODIES AND METHODS OF USESeptember 2022June 2025Allow3300YesNo
17820440CHIMERIC ANTIGEN RECEPTORS TARGETED TO PSCAAugust 2022October 2025Allow3811YesNo
17795949ANTI-ROR1 ANTIBODIES AND COMPOSITIONSJuly 2022September 2025Allow3810YesNo
17795172CHIMERIC ANTIGEN RECEPTOR FOR RECOGNIZING FC FRAGMENT AND APPLICATION THEREOFJuly 2022October 2025Allow3801YesNo
17811645ANTIBODIES TO CD70July 2022September 2025Abandon3810NoNo
17860014CD127 EXPRESSION INVERSELY CORRELATES WITH FOXP3 AND SUPPRESSIVE FUNCTION OF CD4+ TREGSJuly 2022August 2025Allow3710YesNo
17791056ANTI-TNFR2 ANTIBODY AND USES THEREOFJuly 2022January 2026Allow4201YesNo
17854227LAG3 Binding PeptidesJune 2022August 2024Allow2621YesNo
17851944Antibodies to MASP-2June 2022September 2025Abandon3910NoNo
17846580Glycan-Interacting Compounds and Methods of UseJune 2022September 2025Abandon3910NoNo
17844982T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONSJune 2022July 2023Allow1321NoNo
17839963IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS, AND IMMUNOTOXINSJune 2022September 2025Abandon3910NoNo
17783615HEAVY CHAIN ANTIBODIES BINDING TO CD38June 2022January 2026Abandon4301NoNo
17825861COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINSMay 2022August 2025Abandon3901NoNo
17779711T CELL RECEPTORS TARGETING MUTATIONS IN RNA SPLICING FACTORSMay 2022January 2026Allow4421YesNo
17774333ANTIBODY VARIANT COMBINATIONS AND USES THEREOFMay 2022February 2026Allow4601YesNo
17771465ENGINEERED REGULATORY T CELLApril 2022March 2026Allow4711YesNo
17723098SUBCUTANEOUS ADMINISTRATION OF ANTIBODIES FOR THE TREATMENT OF DISEASEApril 2022September 2025Abandon4131NoNo
17718152METHODS FOR SELECTIVE EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOFApril 2022March 2025Allow3500YesNo
17703542MONOCLONAL ANTIBODIES AND METHODS OF USEMarch 2022December 2025Allow4521YesNo
17762902THERAPEUTIC NEUTRALIZATION ANTIBODIES FOR THE TREATMENT OF PEANUT ALLERGYMarch 2022June 2025Allow3800YesNo
17701283COMPOSITIONS COMPRISING REGULATORY T CELLS AND METHODS OF USING THE SAMEMarch 2022June 2025Abandon3821YesNo
17700160HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLSMarch 2022August 2022Allow510NoNo
17691565COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPYMarch 2022October 2024Allow3201NoNo
17691569T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3March 2022June 2025Allow3921YesNo
17691559METHODS OF USING IL-21 FOR ADOPTIVE IMMUNOTHERAPY AND IDENTIFICATION OF TUMOR ANTIGENSMarch 2022December 2024Abandon3301NoNo
17638923IMMUNE SYNAPSE-STABILIZING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLFebruary 2022January 2024Allow2311YesNo
17680021ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPESFebruary 2022December 2024Abandon3401YesNo
17753021Anti-VHH Domain Antibodies and Use ThereofFebruary 2022September 2025Allow4311NoNo
17668134RADIOCONJUGATES DIRECTED TO MHC-COMPLEXED ANTIGENS IN CANCERFebruary 2022September 2024Abandon3132YesNo
17575577NOVEL MODULATORSJanuary 2022March 2025Allow3811YesNo
17561065METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONSDecember 2021September 2024Allow3311NoNo
17559382MONOCLONAL ANTIBODY AND A METHOD OF USE FOR THE TREATMENT OF LUPUSDecember 2021February 2025Allow3800NoNo
17559935BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIADecember 2021August 2023Allow2031YesYes
17620329COMBINATION THERAPY WITH CD13-TARGETED CHIMERIC PROTEINS OR CHIMERIC PROTEIN COMPLEXESDecember 2021October 2025Allow4611YesNo
17620148IMPROVEMENTS TO WASH SOLUTIONS FOR PROTEIN A CHROMATOGRAPHY IN AN ANTIBODY PURIFICATION PROCESSDecember 2021January 2026Abandon4911NoNo
17551861C3D CELLULAR AND ACELLULAR VACCINES FOR THE PREVENTION AND TREATMENT OF CANCERDecember 2021October 2025Allow4620YesNo
17551515PURIFIED ANTIBODY COMPOSITIONDecember 2021August 2025Abandon4401NoNo
17544539COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENSDecember 2021August 2022Allow911YesNo
17615546APJ MODULATORS AND USES THEREOFNovember 2021December 2025Abandon4910NoNo
17535318ANTI-MUTATED KRAS T CELL RECEPTORSNovember 2021January 2025Allow3811YesNo
17528836T CELL WHICH EXPRESSES A GAMMA-DELTA T CELL RECEPTOR (TCR) AND A CHIMERIC ANTIGEN RECEPTOR (CAR)November 2021February 2025Allow3911NoNo
17610325REGULATORY T CELLS TARGETED BY LYMPHOTOXIN ALPHA BLOCKING AGENT AND USES THEREOFNovember 2021July 2024Allow3201YesNo
17516350BISPECIFIC BINDING MOLECULESNovember 2021December 2024Allow3700NoNo
17513621IMMUNOGLOBULINS BINDING HUMAN VGAMMA9VDELTA2 T CELL RECEPTORSOctober 2021March 2022Allow401YesNo
17512195COMPOSITIONS AND METHODS FOR MODULATING DELTA GAMMA CHAIN MEDIATED IMMUNITYOctober 2021April 2024Allow3021YesNo
17511218ANTI-ALPHABETATCR ANTIBODYOctober 2021June 2025Allow4312YesNo
17505515CELLS COMPRISING NON-HLA RESTRICTED T CELL RECEPTORSOctober 2021June 2023Abandon1941YesYes
17496580COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS FOR DIRECT RECOGNITION OF TUMOR ANTIGENOctober 2021March 2025Allow4210NoNo
17494610FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASEOctober 2021November 2024Abandon3712NoNo
17493386HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLSOctober 2021February 2022Allow410YesNo
17493685ENGINEERED GAMMA DELTA T-CELLSOctober 2021March 2025Allow4111NoNo
17479898SURROGATE CO-RECEPTORS FOR T CELLS AND METHODS OF USESeptember 2021November 2025Allow5011YesNo
17475686TCR-ENRICHED CLONOTYPE, ACQUISITION METHOD AND USE THEREOFSeptember 2021January 2025Allow4011YesNo
17470386Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationSeptember 2021June 2025Abandon4511NoNo
17436933T CELL RECEPTORS AND METHODS OF USE THEREOFSeptember 2021September 2025Allow4811NoNo
17463605T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONSSeptember 2021August 2025Allow4722YesNo
17400038ENHANCED GENERATION OF CYTOTOXIC T-LYMPHOCYTES BY IL-21 MEDIATED FOXP3 SUPPRESSIONAugust 2021August 2025Abandon4821NoNo
17397656NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAMEAugust 2021February 2025Abandon4211YesNo
17397841IDENTIFICATION AND USE OF T CELL EPITOPES IN DESIGNING DIAGNOSTIC AND THERAPEUTIC APPROACHES FOR COVID-19August 2021December 2022Abandon1621YesNo
17393682CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3August 2021March 2024Allow3110NoNo
17372070Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationJuly 2021June 2024Abandon3510NoNo
17361524T CELL RECEPTORSJune 2021November 2024Abandon4111NoNo
17304924BCMA T CELL-ANTIGEN COUPLERS AND USES THEREOFJune 2021May 2022Allow1111YesNo
17353409HUMAN ALPHA FETOPROTEIN-SPECIFIC T CELL RECEPTORS AND USES THEREOFJune 2021August 2024Allow3801YesNo
17345425REDIRECTED CELLS WITH MHC CHIMERIC RECEPTORS AND METHODS OF USE IN IMMUNOTHERAPYJune 2021November 2024Abandon4111NoNo
17338972COMPOSITIONS AND METHODS FOR IMMUNOTHERAPYJune 2021January 2025Abandon4341YesNo
17327232BCMA-CAR-NATURAL KILLER (NK) CELLS AND METHODS RELATED THERETOMay 2021August 2021Allow300YesNo
17313761METHOD OF DETECTING NEW IMMUNOGENIC T CELL EPITOPES AND ISOLATING NEW ANTIGEN-SPECIFIC T CELL RECEPTORS BY MEANS OF AN MHC CELL LIBRARYMay 2021September 2024Allow4111YesNo
17307351USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREONMay 2021April 2025Abandon4720NoYes
17243932PEPTIDES FROM NPSR1April 2021February 2024Abandon3401NoNo
17290188BINDING DOMAINApril 2021December 2024Allow4410NoNo
17289690METHODS FOR SELECTION AND STIMULATION OF CELLS AND APPARATUS FOR SAMEApril 2021September 2025Allow5211NoNo
17287307T-CELL RECEPTOR CONSTANT REGION 1 ANTIBODY OR T-CELL RECEPTOR CONSTANT REGION 2 ANTIBODYApril 2021February 2024Allow3400YesNo
17234726METHODS OF TREATING POLYCYSTIC KIDNEY DISEASEApril 2021June 2024Allow3811NoNo
17226987Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell TransplantApril 2021October 2023Allow3010NoNo
17281574COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA DELTA T-CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORSMarch 2021March 2026Allow6021YesNo
17217837METHODS FOR INHIBITING FIBROSIS IN A SUBJECT IN NEED THEREOFMarch 2021October 2024Abandon4220NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SKELDING, ZACHARY S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
5
(55.6%)
Examiner Reversed
4
(44.4%)
Reversal Percentile
66.9%
Higher than average

What This Means

With a 44.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
133
Allowed After Appeal Filing
14
(10.5%)
Not Allowed After Appeal Filing
119
(89.5%)
Filing Benefit Percentile
13.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 10.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SKELDING, ZACHARY S - Prosecution Strategy Guide

Executive Summary

Examiner SKELDING, ZACHARY S works in Art Unit 1644 and has examined 1,078 patent applications in our dataset. With an allowance rate of 55.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner SKELDING, ZACHARY S's allowance rate of 55.9% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SKELDING, ZACHARY S receive 1.75 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SKELDING, ZACHARY S is 38 months. This places the examiner in the 29% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +52.0% benefit to allowance rate for applications examined by SKELDING, ZACHARY S. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.9% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 36.6% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 86.2% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 83.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 47.5% are granted (fully or in part). This grant rate is in the 42% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.2% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 64% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.